Intellectus Partners’s Crescent Biopharma, Inc. Common Stock CBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-460
| Closed | -$9.65K | – | 286 |
|
|
2025
Q1 | $9.65K | Hold |
460
| – | – | ﹤0.01% | 267 |
|
|
2024
Q4 | $11.4K | Hold |
460
| – | – | ﹤0.01% | 272 |
|
|
2024
Q3 | $7.77K | Hold |
460
| – | – | ﹤0.01% | 264 |
|
|
2024
Q2 | $12.9K | Sell |
460
-47
| -9% | -$1.32K | ﹤0.01% | 258 |
|
|
2024
Q1 | $152K | Hold |
507
| – | – | 0.04% | 249 |
|
|
2023
Q4 | $120K | Sell |
507
-113
| -18% | -$26.7K | 0.03% | 239 |
|
|
2023
Q3 | $93K | Sell |
620
-115
| -16% | -$17.2K | 0.03% | 250 |
|
|
2023
Q2 | $128K | Sell |
735
-82
| -10% | -$14.3K | 0.04% | 253 |
|
|
2023
Q1 | $103K | Hold |
817
| – | – | 0.03% | 243 |
|
|
2022
Q4 | $248K | Sell |
817
-388
| -32% | -$118K | 0.09% | 218 |
|
|
2022
Q3 | $66K | Buy |
1,205
+325
| +37% | +$17.8K | 0.02% | 249 |
|
|
2022
Q2 | $53K | Sell |
880
-25
| -3% | -$1.51K | 0.02% | 239 |
|
|
2022
Q1 | $103K | Buy |
905
+100
| +12% | +$11.4K | 0.03% | 228 |
|
|
2021
Q4 | $116K | Sell |
805
-425
| -35% | -$61.2K | 0.03% | 260 |
|
|
2021
Q3 | $269K | Hold |
1,230
| – | – | 0.07% | 232 |
|
|
2021
Q2 | $285K | Buy |
1,230
+420
| +52% | +$97.3K | 0.06% | 238 |
|
|
2021
Q1 | $244K | Buy |
810
+710
| +710% | +$214K | 0.07% | 228 |
|
|
2020
Q4 | $38K | Buy |
+100
| New | +$38K | 0.01% | 230 |
|